Quantcast
Last updated on April 16, 2014 at 17:32 EDT

Latest drug discovery Stories

2014-02-07 08:22:40

NEW DELHI, February 7, 2014 /PRNewswire/ -- KuicK Research releases "Global Orphan Drug Market Outlook 2018" research report offering comprehensive insight on recent trends, regulatory development related to US orphan drug market, Europe orphan drug market & Asia orphan drug market. Report also gives insight on more than 600 orphan drugs in clinical pipeline and 231 marketed orphan drugs. Global Orphan Drug Market Report Findings: - Orphan...

2014-02-06 16:28:11

Interim Outcomes in CHOCOLATE BAR Registry Demonstrate High Rates of Procedural Success and Limb Preservation PLEASANTON, Calif. and SINGAPORE, Feb. 6, 2014 /PRNewswire/ -- Interim results from The CHOCOLATE® BAR Registry conducted in the US demonstrate that use of the CHOCOLATE® PTA balloon achieved high rates of treatment success and limb preservation in patients with peripheral arterial disease. The results from the first 350 patients enrolled and treated were presented by Dr. Tony Das...

2014-02-06 08:29:23

BUFFALO, N.Y., Feb. 6, 2014 /PRNewswire/ -- Kinex Pharmaceuticals and PharmaEssentia Corporation (Taiwan) announced today the execution of a new licensing agreement granting PharmaEssentia exclusive development and commercial rights to Oraxol and Oratecan in Taiwan and Singapore. Kinex will receive an upfront payment, milestones, and royalties. PharmaEssentia has also committed to conducting clinical studies in Taiwan to contribute to the global registration programs for Oraxol...

2014-02-06 08:28:26

New cloud solution for externalized life science research and development redefines collaboration and creativity SAN DIEGO, Feb. 6, 2014 /PRNewswire/ - Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, has announced the launch of ScienceCloud, a new SaaS-based information management and collaboration workspace. ScienceCloud advances collaborative drug discovery with a new generation of integrated applications built on a scalable,...

2014-02-05 08:30:51

BUFFALO, N.Y., Feb. 5, 2014 /PRNewswire/ -- Kinex Pharmaceuticals, (Kinex), a leading specialty biotech focused on the development and commercialization of next generation oral therapies for cancer diseases has appointed Dr. Rudolf Kwan, as Chief Medical Officer and Dr. Wing-Kai Chan as Head of Clinical Operations- Asia/Pacific. Kinex currently has four oral oncology drug candidates allowed in the clinic and the appointments of Dr. Kwan and Dr. Chan adds significant expertise in...

2014-02-05 08:28:40

Accelerates development of BGB324, the only selective Axl kinase inhibitor in the clinic BERGEN, Norway, February 5, 2014 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, announces that it has raised NOK75 million (c.$12.5 million) from a syndicate of new and existing investors through a private placement. This follows a $6.0 million round in May 2013. Proceeds from the financing will be used to support the development...

2014-02-05 08:28:35

SAN FRANCISCO and LONDON, Feb. 5, 2014 Drugs.com, the leading online clinical drug resource, and TrialReach are partnering to provide patients with information and access to treatments that are still under development. Announced today at Rock Health, this new partnership will bring TrialReach's patient-centric content and tools directly to the 25+ million people who visit Drugs.com every month. From a patient's perspective, clinical trials offer more treatment options when the...

2014-02-04 23:00:35

EPI-743 phase 2b Friedreich's ataxia trial fully enrolled. Downingtown, PA (PRWEB) February 04, 2014 Edison Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to vatiquinone (EPI-743) for the treatment of Friedreich’s ataxia (http://www.prnewswire.com/news-releases/fda-grants-edison-pharmaceuticals-epi-743-orphan-status-for-friedreichs-ataxia-243439351.html). Orphan status brings additional momentum and acceleration to the...

2014-02-04 12:26:07

DALLAS, February 4, 2014 /PRNewswire/ -- According to the new market research report, the "High Throughput Screening (HTS) Market by Technology (Cell Based, Ultra High Throughput Screening (UHTS), Label Free, Bioinformatics), by Applications (Target Identification, Primary Screening, Toxicology, Stem Cell), by End Users (Pharmaceutical Industry, Biotechnology Industry, CRO) - Forecast to 2018", analyzes and studies the major market drivers, restraints, and opportunities in...

2014-02-04 08:34:50

LONDON, Feb. 4, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H2, 2013 Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H2, 2013SummaryGlobalData's clinical trial report, "Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H2, 2013" provides data on the Chemotherapy Induced Nausea and Vomiting clinical trial scenario. This report...